Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greater development space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services. Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns. Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise. By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
Shennapsi Artificial Intelligence Technology
Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Power Site
Series B in 2023
Power Site is a modern technology enterprise that supplies X-ray imaging core components. It mainly provides high-voltage generators (HVG), combined X-ray sources, power distribution units (PDU), and other core components overall solutions for X-ray imaging systems. The products are mainly used in high-end X-ray imaging systems such as CT, DR, mammography, C-arm, CBCT, security inspection, industrial inspection, etc. The company has an advanced and efficient manufacturing platform with an annual production capacity of 50,000 units.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Hanchao Pharmaceuticals
Venture Round in 2023
Hanchao Pharmaceuticals is a biopharmaceutical manufacturer that develops medicines and other medical equipment.
Pulnovo Medical
Venture Round in 2022
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Zhongguancun Shuimu Medical Technology
Series A in 2022
Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.
JoyMed Technology
Series B in 2022
JoyMed Technology specializes in the research and development, registration, and manufacturing of medical devices, offering comprehensive solutions to medical equipment manufacturers. The company focuses on creating innovative and reliable technologies while ensuring high-quality product standards. By providing services such as device design, risk management, marketing, and product verification and validation, JoyMed Technology helps clients streamline their processes and reduce time to market. The firm aims to be a trusted partner for both domestic and international medical device companies, particularly assisting small and medium-sized enterprises in navigating the complexities of the medical product market. Through a flexible cooperation model and experienced team design, JoyMed Technology seeks to foster mutual growth with its customers.
Tripod Preclinical Research
Venture Round in 2021
Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.
Guangzhou Creative Biosciences
Series D in 2021
Creative Biosciences is a biomedical technology company focused on developing and producing diagnostic products for tumor screening, particularly in the realm of colorectal cancer. The company specializes in fecal DNA detection technology, providing non-invasive screening kits that allow medical practitioners to accurately identify genetic abnormalities in fecal samples. These diagnostic tools are designed to aid in the early detection of intestinal cancer lesions, thereby supporting healthcare professionals and researchers in their efforts to improve cancer treatment outcomes. Through its innovative approach, Creative Biosciences aims to enhance cancer screening processes and contribute to better patient care.
Vision X
Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.
IntoCare
Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Synaptic Medical
Series G in 2021
Synaptic Medical Inc. is a medical device company that develops and commercializes products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Founded in 2005, the company operates from its headquarters in St. Paul, Minnesota, and has an additional office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology products, including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation technologies. The company's mission is to create innovative, cost-effective, and clinically advanced solutions that enhance treatment options for physicians and their patients.
HuiKai
Series A in 2021
HuiKai Medical focuses on the research and development, as well as the manufacturing of medical devices tailored for the urinary system. The company's product range addresses various urological conditions, including prostatic hyperplasia, urinary stones, urinary incontinence, and urological tumors. By employing proprietary technology and innovative materials, HuiKai Medical aims to enhance patient comfort and streamline procedures, thereby improving overall healthcare efficiency and outcomes.
Yingsheng Biology
Series B in 2020
Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.
GensKey
Series C in 2020
GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. Utilizing high-throughput sequencing technology and intelligent algorithm analysis, GensKey addresses traditional challenges such as low detection rates, lengthy processes, and diagnostic accuracy. This innovative approach allows for timely and precise diagnoses for patients suffering from severe infections, ultimately improving patient outcomes by facilitating quicker access to appropriate medical interventions.
Zylox
Series C in 2020
Zylox Medical Device Co. was established in 2012 in Hangzhou by a team of experienced professionals who returned to China after working in prominent medical device companies in the US and Europe. The company specializes in developing innovative interventional and implantable devices for peripheral and neurovascular applications. Its product portfolio includes a range of devices such as PTA balloons, drug-coated PTA balloons, stents, and thrombectomy devices. Zylox is committed to providing high-quality medical solutions aimed at improving patient care and enhancing the capabilities of healthcare professionals. The company continues to expand its product offerings to address various vascular conditions both in China and internationally.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Ruixun Biotech
Series A in 2019
Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.
DiaMonTech
Series A in 2019
DiaMonTech AG is a medical technology company based in Berlin, Germany, focused on developing non-invasive diagnostic devices for blood glucose monitoring. Founded in 2015, the company utilizes a proprietary laser-based photo-thermal detection technology to measure glucose levels without the need for blood draws or finger pricking, thereby offering a painless alternative for diabetes management. DiaMonTech's product lineup includes the D-BASE, a device designed for human trials, the D-pocket, a compact personal device for frequent glucose tracking, and the D-BAND, a wearable device that continuously monitors blood sugar levels. Through its innovative solutions, DiaMonTech aims to enhance the quality of life for individuals managing diabetes.
Just Medical
Series A in 2019
Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial implants such as hip and knee joints, as well as internal fixation products and surgical instruments. The company emphasizes research and development in orthopedics, aiming to enhance surgical efficiency and improve the quality of orthopedic treatment. Just Medical is dedicated to providing safe and effective medical products and services, continually refining its product systems to alleviate patient pain and support healthcare professionals in their surgical procedures.
Joinspine
Series A in 2019
Joinspine is one of the few Chinese companies that have some core patients in the field of spinal surgery and spine endoscopy industry. The current team is using the latest new technologies to improve its auxiliary robot and AI. Based on advanced foreign technologies and their own Development, Jlecheng Medical believes they can help this industry to improve in China.
Yingsheng Biology
Series C in 2019
Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.
DeepCyto
Venture Round in 2019
DeepCyto is a medtech company established in 2018 and headquartered in Suzhou, Jiangsu, China. The company specializes in the development of digital hematology pathology and diagnostic equipment, integrating artificial intelligence and deep learning technologies into medical diagnosis and data analysis. By leveraging machine vision and big data mining, DeepCyto offers intelligent diagnostic models for a range of blood diseases, enhancing the accuracy and efficiency of medical assessments.
Novaprint Therapeutics
Venture Round in 2019
Novaprint Therapeutics develops and supplies regenerative medical implant devices. The company utilizes 3D printing technology to design and develop regenerative medical implant devices, enabling patients to receive more customized and effective medical treatment.
AGS MedTech
Series A in 2018
AGS MedTech specializes in the design, development, and production of endoscopic, minimally invasive devices for interventional diagnosis and treatment. The company focuses on research and development to create innovative solutions that enhance patient care while reducing pain and medical costs. By prioritizing safety and efficiency, AGS MedTech aims to provide both patients and clinicians with advanced tools that facilitate effective medical procedures.
Innovita Biological Technology
Series B in 2018
Established in 2006 in Beijing, Innovita Biological Technology Co., Ltd. is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. In 2011 Innovita extended a new plant in Tangshan city of Hebei province-Innovita (Tangshan) Biological Technology Co., Ltd., which was designed as five new production lines: colloidal gold, real-time PCR, chemiluminescence, ELISA and biochips. The facility covers 250 acres (160,000 square meters) and is equipped with a purification plant of 4,000 square meters. The designed annual output can reach 20 million tests. Currently they have got ten invention patents. With certification of CE, ISO 13485 and GMP, Innovita has an extensive product line covering Fertility, Infectious Diseases, Sexually Transmitted Diseases, TORCH, Respiratory Diseases, Drug Abuse, Tumor Marker and Cardiac marker tests.
Cryofocus Biotech
Series A in 2018
Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy.
KingstronBio
Series A in 2016
KingstronBio manufactures artificial heart valves and annuloplasty rings.
Dymind
Venture Round in 2016
Dymind specializes in the development, manufacture, sale, and service of medical devices.
inui
Series B in 2015
inui Health is a consumer medical diagnostics company based in Silicon Valley. Their vision is to make medical-grade information accessible anytime, anywhere. Their cloud-based diagnostic platform works in a mobile environment to empower consumers with access to their own health information. Their products will help consumers detect complications early, monitor their health, and easily share their health information so they can work with their healthcare provider for timely interventions. The first product to be released will be the inui In-Home Urine Analysis test system, which provides patients and physicians with immediate lab test results.
Admera
Series A in 2015
Admera Health, LLC is a molecular diagnostics company based in South Plainfield, New Jersey, specializing in personalized medicine and non-invasive cancer testing. The company operates a laboratory dedicated to developing, validating, and delivering proprietary laboratory-developed tests. Among its offerings are PGxOne, a pharmacogenomics test that assesses patient drug responses based on genetic profiles, and DNA sequencing services for analyzing genetic mutations related to cancer. Admera's product pipeline includes the OncoGxOne cancer panel, which identifies genomic variations associated with cancer and treatment options, as well as the FloraCheck microbiome test that evaluates bacterial composition in relation to health. Founded in 2012, Admera Health aims to meet medical needs through innovative diagnostics, utilizing next-generation sequencing and advanced bioinformatics to enhance patient care and outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.